These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28494126)

  • 1. Real-life glycemic control in patients with type 2 diabetes treated with insulin therapy: A prospective, longitudinal cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 9]).
    Fujita N; Yamamoto Y; Hayashino Y; Kuwata H; Okamura S; Iburi T; Furuya M; Kitatani M; Yamazaki S; Ishii H; Tsujii S; Inagaki N; Fukuhara S;
    J Diabetes Investig; 2018 Mar; 9(2):294-302. PubMed ID: 28494126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(®) study.
    Hwang YC; Kang JG; Ahn KJ; Cha BS; Ihm SH; Lee S; Kim M; Lee BW
    Int J Clin Pract; 2014 Nov; 68(11):1338-44. PubMed ID: 25284679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Wang C; Mamza J; Idris I
    Diabet Med; 2015 May; 32(5):585-94. PubMed ID: 25594251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
    Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
    Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 3).
    Mashitani T; Hayashino Y; Okamura S; Kitatani M; Furuya M; Matsunaga S; Kuwata H; Tsujii S; Ishii H
    Diabetes Res Clin Pract; 2013 May; 100(2):189-94. PubMed ID: 23522915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.
    Shanmugasundar G; Bhansali A; Walia R; Dutta P; Upreti V
    Indian J Med Res; 2012; 135(1):78-83. PubMed ID: 22382187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practice.
    Tibaldi JT
    Adv Ther; 2007; 24(6):1348-56. PubMed ID: 18165218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Koivisto V; Cleall S; Pontiroli AE; Giugliano D
    Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
    Jovanovič L; Peters AL; Jiang HH; Hardin DS
    Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes - a nationwide evaluation of clinical practice.
    Mungreiphy NK; Mamza J; Lakhdar AF; Bannister M; Elliott J; Idris I
    Curr Med Res Opin; 2015 Mar; 31(3):493-501. PubMed ID: 25597325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.